Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L de Vos

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
British Journal of Cancer|April 7, 2026
Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trialMaarten A Huismans, Eelke H Gort, Lisa T van der Heijden, et al.
Nature Medicine|April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialVivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
The Oncologist|December 18, 2023
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery ProtocolIlse A C Spiekman, Birgit S Geurts, Laurien J Zeverijn, et al.
Clinical Nuclear Medicine|December 19, 2023
The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?Bernies van der Hiel, Else A Aalbersberg, Alfons J M van den Eertwegh, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
Journal of Thrombosis and Haemostasis : JTH|August 19, 2021
Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancerNoori A M Guman, Roos J van Geffen, Frits I Mulder, et al.
Circulation. Genomic and Precision Medicine|April 10, 2026
Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid CancerFrits I Mulder, Noori A M Guman, Job van Riet, et al.
International Journal of Cancer|July 10, 2023
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trialsLaurien J Zeverijn, Eleonora J Looze, Subotheni Thavaneswaran, et al.
Trials|June 17, 2025
[<sup>18</sup>F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trialV J Ruijters, T J Snijders, J A J van der Pol, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
British Journal of Cancer|April 7, 2026
Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trialMaarten A Huismans, Eelke H Gort, Lisa T van der Heijden, et al.
Nature Medicine|April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialVivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
The Oncologist|December 18, 2023
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery ProtocolIlse A C Spiekman, Birgit S Geurts, Laurien J Zeverijn, et al.
Clinical Nuclear Medicine|December 19, 2023
The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?Bernies van der Hiel, Else A Aalbersberg, Alfons J M van den Eertwegh, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
Journal of Thrombosis and Haemostasis : JTH|August 19, 2021
Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancerNoori A M Guman, Roos J van Geffen, Frits I Mulder, et al.
Circulation. Genomic and Precision Medicine|April 10, 2026
Tumor Whole-Genome Sequencing for Prediction of Venous Thromboembolism in Patients With Metastasized Solid CancerFrits I Mulder, Noori A M Guman, Job van Riet, et al.
International Journal of Cancer|July 10, 2023
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trialsLaurien J Zeverijn, Eleonora J Looze, Subotheni Thavaneswaran, et al.
Trials|June 17, 2025
[<sup>18</sup>F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trialV J Ruijters, T J Snijders, J A J van der Pol, et al.
Pageof 11